Meenakshi Prabhune, PhD | Feb 23, 2024 | 10 min read
With deep learning methods revolutionizing life sciences, researchers bet on de novo proteins and cell mapping models to deliver customized precision medicines.
Clinical trials that target human endogenous retroviruses to treat multiple sclerosis, ALS, and other ailments are underway, but many questions remain about how these sequences may disrupt our biology.
Researchers have sequenced the genomes of 17 different mouse strains, boosting research into the genetic basis of phenotypic variation, disease, and evolution.
This year’s crop of winning products features many with a clinical focus and others that represent significant advances in sequencing, single-cell analysis, and more.
A reference sequence for this emerging model organism will facilitate research on type 2 diabetes and the health effects of circadian rhythm disruption.